Pfizer beats estimates but share price slips

2 August 2016

US pharma giant Pfizer (NYSE: PFE) beat earnings expectations with its 2nd-qtr 2016 financial results, but markets responded negatively as its share price dropped by more than 2% to $36.41 in Tuesday morning’s trading.

The company’s sales for the quarter totalled $13.15 billion, which is 11% higher than in the same period of 2015, though its reported net income was 23% down on a year ago, at $2.02 billion.

Pfizer beat the predictions of Wall Street analyst. Its adjusted earnings amounted to $0.64 per share, two cents better than analysts estimated, and sales exceeded expectations by $150 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK